Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.

Wasada, Taro; Kawahara, Reiko; Iwamoto, Yukihide

doi:10.2337/diacare.23.7.1039

Cited by 17 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When bromocriptine-QR is given in the morning, the evening peak of prolactin returns, while standard bromocriptine results in a more prolonged suppression of prolactin. It should also be noted that in the study by Wasada et al [49], standard release bromocriptine failed to improve glycaemia control. In animal experiments, the timing of bromocriptine-QR administration is important and the effect on insulin resistance is lost when the administration of bromocriptine is given 6 h later than the optimal timings.…”

Section: Implications For Standard Release Bromocriptine and Other Domentioning

confidence: 95%

Bromocriptine: old drug, new formulation and new indication

Holt

Barnett

Bailey

2010

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Bromocriptine is an ergot alkaloid dopamine D(2) receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR-bromocriptine lowers glycated haemoglobin by 0.6-1.2% (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.

show abstract

Section: Implications For Standard Release Bromocriptine and Other Domentioning

confidence: 95%

Bromocriptine: old drug, new formulation and new indication

Holt

Barnett

Bailey

2010

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Human studies show similar effects, though the results are not as profound 20–25. Dosages of bromocriptine in human trials have ranged from 2.5 mg to 5 mg per day.…”

Section: Mechanism Of Actionmentioning

confidence: 98%

“…In the current literature, there are 6 clinical trials using bromocriptine therapy for the treatment of T2DM and/or obesity 20–25. The results of these studies are summarized in Table 1 and reviewed below.…”

Section: Published Clinical Trialsmentioning

confidence: 99%

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Via¹

2010

DMSOTT

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and worldwide. Despite advances in medical treatments for T2DM, many patients remain uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocriptine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate improvements in insulin resistance and glycemic control. After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of bromocriptine in T2DM. We review the available data from these four trials and other published studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control.

show abstract

“…In rodents bromocriptine has been shown to decrease body weight and body fat [87]. In humans, administration of bromocriptine and a quick release form of this drug to obese non-hyperprolactinemic individuals decreased percent body fat, lipid parameters and insulin resistance [88][89][90], although not consistently [91].…”

Section: Inflammatory Markersmentioning

confidence: 99%

The effects of hyperprolactinemia on bone and fat

2008

View full text Add to dashboard Cite

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.

show abstract

Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.

Cited by 17 publications

References 0 publications

Bromocriptine: old drug, new formulation and new indication

Bromocriptine: old drug, new formulation and new indication

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

The effects of hyperprolactinemia on bone and fat

Contact Info

Product

Resources

About